Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash & Equivalents (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Cash & Equivalents for 12 consecutive years, with $90000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 119.51% year-over-year to $90000.0, compared with a TTM value of $90000.0 through Sep 2025, up 119.51%, and an annual FY2024 reading of $19000.0, up 1800.0% over the prior year.
  • Cash & Equivalents was $90000.0 for Q3 2025 at Avalo Therapeutics, up from $20000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $16.7 million in Q1 2023 and bottomed at $1000.0 in Q3 2023.
  • Average Cash & Equivalents over 5 years is $973944.4, with a median of $41000.0 recorded in 2021.
  • The sharpest move saw Cash & Equivalents soared 16587.0% in 2023, then plummeted 99.98% in 2024.
  • Year by year, Cash & Equivalents stood at $51000.0 in 2021, then plummeted by 70.59% to $15000.0 in 2022, then crashed by 93.33% to $1000.0 in 2023, then skyrocketed by 1800.0% to $19000.0 in 2024, then soared by 373.68% to $90000.0 in 2025.
  • Business Quant data shows Cash & Equivalents for AVTX at $90000.0 in Q3 2025, $20000.0 in Q2 2025, and $62000.0 in Q1 2025.